Menu
Not yet recruiting NCT06847477

SOFA Score with Serum Procalcitonin Versus SOFA Score with Neutrophil/lymphocyte Ratio in Predicting Sepsis and Clinical Outcomes in I.C.U.

Observational Sepsis Critical Illness

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Sepsis, Critical Illness. Basic parameters: from 18 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

SOFA Score with Serum Procalcitonin Versus SOFA Score with Neutrophil/lymphocyte Ratio in Predicting Sepsis and Clinical Outcomes in Intensive Care Unit.

Overview

Sepsis remains a critical life-threatening and a healthcare challenge worldwide. Sepsis is implicated in a mortality rate that ranges between 25 - 30% in severe cases and 40-70% in septic shock, also, Post sepsis, lower quality of life was observed among survivors, therefore early prediction and a rapid therapeutic decision, are essential to improve patient outcomes. Different indicators are proposed as predictors but with different sensitivity, specificity, and availability. This study aims to evaluate the efficacy of PCT and SOFA scores versus SOFA and NLR in predicting morbidity and mortality outcomes in sepsis.

Detailed description

Sepsis provokes a dysregulated host response to infection that leads to acute organ dysfunction. The subsequent Septic shock, which includes an underlying circulatory and cellular imbalance increases the mortality. Septic shock manifests as persistent hypotension requiring vasopressors to maintain a mean arterial pressure of 65 mm Hg or higher and a serum lactate level greater than 2 mmol/L (18 mg/dL) in the absence of hypovolemia.

Sequential Organ Failure Assessment score (SOFA) has become extensively used and one of the gold standard tests in assessing the patient's status during intensive care unit (ICU) stay and predicting the clinical outcomes of the patients, however, poor sensitivity of SOFA score is a major limitation that excludes its use as a screening tool for early sepsis, the stage in which treatment is most effective. Blood culture is a well-established diagnostic test for sepsis, however, has limitations e.g. prolonged incubation time and probability of false-negative results.

Procalcitonin (PCL) has been studied as a sepsis biomarker, to help with sepsis diagnosis and to guide the initiation and cessation of antibiotics. Procalcitonin strongly correlates with the extent and severity of bacterial infections, better indicator of illness severity than CRP, and also, provides a quick result compared to blood cultures. Procalcitonin use may be hindered by availability and the cost in a limited resources environment, However, The neutrophil-to-lymphocyte ratio (NLR) is a readily available marker. The neutrophil-to-lymphocyte ratio (NLR) is an indicator of systemic inflammation based on complete blood count values. In general, blood neutrophil count increases with the progress of the inflammatory disease, NLR is more reliable when predicting patient survival than either neutrophil count or lymphocyte count alone.

Endogenous cortisol and catecholamines increase the neutrophil count while simultaneously decreasing the lymphocyte count so it may be major drivers of the NLR. Also, cytokines and other hormones are likely to be involved. So NLR is not solely an indication of infection or inflammation. Any cause of physiologic stress may increase the NLR (e.g. hypovolemic shock). NLR increases rapidly following acute physiologic stress (\<6 hours). This prompt response time may make NLR a better reflection of acute stress. Interpretation of NLR level is as follows: A normal NLR is roughly 1-3, An NLR of 6-9 suggests mild stress and Critically ill patients will often have an NLR of \~9 or higher (occasionally reaching values close to 100).

This research will test the predictability of combined SOFA score and procalcitonin versus combined SOFA score and NLR for clinical outcomes such as length of ICU stay and mortality.

Primary outcome measures

  • Length of ICU stay [Time frame: from the time of admission to the time of discharge from the ICU or death up to 40 days from ICU admission]
Secondary outcome measures (2)
  • 28 days mortality [Time frame: From the day of admission at the ICU and up to 28 days.]
  • Antibiotics used [Time frame: From ICU admission to discharge from ICU or death which comes first up to 40 days from admission.]

Eligibility criteria

Inclusion criteria

  • critically ill patients admitted to ICU for surgical or trauma causes.

Exclusion criteria

  • Lack of consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Publications

  • Kumar R, Kattimani B, Ojha PR, Khasage UJ. Quick Sequential Organ Failure Assessment Score, Lactate, and Neutrophil-Lymphocyte Ratio Help in Diagnosis and Mortality Prediction during Golden Hour of Sepsis in Emergency Department. J Emerg Trauma Shock. 2023 Oct-Dec;16(4):161-166. doi: 10.4103/jets.jets_37_23. Epub 2023 Oct 24. PMID 38292274
  • Bajic D, Matijasevic J, Andrijevic L, Zaric B, Lalic-Popovic M, Andrijevic I, Todorovic N, Mihajlovic A, Tapavicki B, Ostojic J. Prognostic Role of Monocyte Distribution Width, CRP, Procalcitonin and Lactate as Sepsis Biomarkers in Critically Ill COVID-19 Patients. J Clin Med. 2023 Feb 2;12(3):1197. doi: 10.3390/jcm12031197. PMID 36769843

Identifiers

NCT: NCT06847477 · FMASU R24/2025

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗